Ophthalmic Backgrounds Influencing the Efficacy of SGLT2 Inhibitor in Diabetic Macular Oedema: Post‐hoc Analysis of the COMET Trial

Documenti analoghi

• Sodium‐glucose co‐transporter 2 inhibitors reduce the intravitreal anti‐ VEGF treatment necessity in eyes with early diabetic macular oedema: A post‐hoc analysis focusing on the fellow eye of the COMET trial
  di: Tomoaki Tatsumi, et al.
  Pubblicazione: (2025)
• Blood Pressure Status Modulates the Therapeutic Response to Sodium‐Glucose Cotransporter 2 Inhibitors in Diabetic Macular Edema: A Post Hoc Subgroup Analysis of the COMET Trial
  di: Ryoichi Ishibashi, et al.
  Pubblicazione: (2025)
• Sodium–glucose cotransporter 2 inhibition and injection burden in mild diabetic macular edema: An exploratory post hoc analysis of the COMET trial
  di: Yoko Takatsuna, et al.
  Pubblicazione: (2026)
• Effects of the SGLT2 inhibitor ipragliflozin and metformin on hepatic steatosis and liver fibrosis: Sub‐analysis of a randomized controlled study
  di: Kiichi Hirayama, et al.
  Pubblicazione: (2025)
• Impaired insulin receptor function alters psychiatric behaviors without affecting circadian rhythms in a mouse model of Alzheimer's disease
  di: Naotaka Izuo, et al.
  Pubblicazione: (2025)